Major Depressive Disorder: Treatment Landscape, Adjunctive Antipsychotic Evidence, and Managed Care Implications

EP. 1: The Burden of Major Depressive Disorder: Setting the Stage for Managed Care

ByKen Cohen, MD,Samuel Wilkinson, MD,Greg Rhee, PhD, FACE,Michael E. Thase, MD,Nisha Bhide, PharmD

August 27th 2026

Welcome back to another AJMC Peer Exchange series. In this episode titled, "The Burden of Major Depressive Disorder: Setting the Stage for Managed Care."

EP. 2: Remission vs. Response: Redefining Treatment Goals in Major Depressive Disorder

ByKen Cohen, MD,Samuel Wilkinson, MD,Greg Rhee, PhD, FACE,Michael E. Thase, MD,Nisha Bhide, PharmD

August 27th 2026

Major depressive disorder (MDD) is a heterogeneous disorder with many unique symptom combinations.

Major Depressive Disorder: Treatment Landscape, Adjunctive Antipsychotic Evidence, and Managed Care Implications

EP. 1: The Burden of Major Depressive Disorder: Setting the Stage for Managed Care

EP. 2: Remission vs. Response: Redefining Treatment Goals in Major Depressive Disorder

Trending on AJMC

Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug

As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning

ACO-SWITCH to Evaluate Tafamidis-to-Acoramidis Switch in ATTR-CM

FAQ: Prior Authorization Reform—Will Changes Go Far Enough by 2027?

Early Secukinumab Sustains Psoriasis Clearance a Year After Stopping